A European Medicines Agency committee has confirmed that there is a small increase in the risk of cardiovascular problems such as heart attacks and stroke in patients taking high doses – 2,400mg or more – of ibuprofen, and has recommended that the labelling of products containing the anti-inflammatory drug should be updated to reflect this risk.
The Pharmacovigilance Risk Assessment Committee (PRAC) said that the risk with high-dose ibuprofen was similar to that seen with some other non-steroidal anti-inflammatory drugs (NSAIDSs) including diclofenac and the COX-2 inhibitors,